to early changes in respiratory rate (6). In addition, high VT has been linked to patient self-inflicted lung injury (P-SILL) and such may increase intubation rate in patients with AHRF (7). Taken together, from a physiological perspective, elevated VT may be a better predictor for HFNC failure compared with respiratory rate. Hence, we report an approach to measure VT generated by patients supported with HFNC and establish a novel index named VOX (Volume-OXygenation) based on VT to predict HFNC failure in patients with AHRF.

**Methods**
This single-center prospective observational study was performed from May 2021 to January 2022 in a 60-bed ICU at Zhongda Hospital, China. The research premise was granted approval by the local Ethics Committee (2020ZDSYLL303-P01) and registered in the Chinese Clinical Trial Registry (ChiCTR2100046461). All patients admitted to ICU for AHRF and eligible for treatment with HFNC (Optiflow™, Fisher and Paykel) according to clinical protocol were screened for eligibility.

The VOX index was defined as the ratio of SpO₂/FiO₂ over VT. We briefly interrupted HFNC (3 min) to measure VT using a mechanical ventilator (SV800, Mindray) in noninvasive ventilation (NIV) mode, as an “NIV test”. Inspiratory support was set at 5 cmH₂O and 5 cmH₂O positive end-expiratory pressure level for all patients, and initial oxygen concentration was set as in HFNC. NIV was delivered through a face mask (ZS-MZ-A, Zhongshan Medical) and a double-pipe system, while minimizing leaks. In consideration of variations in VT, we recorded mean VT and respiratory rate for 1 minute under stable conditions.

HFNC therapy was started within 15 minutes after recruitment. We adjusted FiO₂ targeting SpO₂ of 92% or more, and the rate of flow was set based on the physician’s judgement. HFNC discontinuation and invasive mechanical ventilation (IMV) initiation were based on the intubation criteria defined in our clinical protocol, final decisions were made by the physicians in charge, who were blinded to the VT during NIV test. HFNC failure was defined as a need for IMV, on account of NIV is not employed as the second line of ventilatory support in the event of HFNC failure, in the participating units. The time of HFNC onset was defined as 0 hours. Vital signs: HFNC settings including FiO₂, flow rate, and temperature; clinical respiratory variables including respiratory rate, VT, and SpO₂ were recorded at 0, 2, 6, 12, 18, and 24 hours following initiation of HFNC treatment. Multivariable logistic regression was performed to explore the association between VOX index and HFNC failure. Receiver-operating characteristic curves (ROC) were generated to show clinical respiratory variables, ROX index and VOX index in predicting the failure of HFNC. Differences between area under the receiver operating curve (AUROC) were estimated using a nonparametric approach, by using the theory on generalized U statistics to generate an estimated covariance matrix (MedCalc software). The maximum value of the Youden’s J statistic was utilized as the selection criteria of the optimum cut-off point of the ROC curves. P < 0.05 signifies statistical significance.

**Results**
Sixty-two patients were enrolled (age 65 ± 12 years, 39 males) and 29 patients (46.8%) failed HFNC. Pneumonia (36/62, 58%) was the primary causes of AHRF; none of the patients were predictors of HFNC failure would be of clinical importance. Initially, elevated respiratory drive increases tidal volume (VT), but not respiratory rate (6). In addition, high VT has been linked to patient self-inflicted lung injury (P-SILL) and such may increase intubation rate in patients with AHRF (7). Taken together, from a physiological perspective, elevated VT may be a better predictor for HFNC failure compared with respiratory rate. Hence, we report an approach to measure VT generated by patients supported with HFNC and establish a novel index named VOX (Volume-OXygenation) based on VT to predict HFNC failure in patients with AHRF.
diagnosed with coronavirus disease (COVID-19). Initial flow rate was 54 ± 6 L/min and FiO₂ was 0.47 ± 0.08. Patients failing HFNC had significantly higher APACHE II score (21.0 ± 5.8 versus 15.2 ± 5.0, P < 0.001), number of quadrants affected on chest-X-ray (2.3 ± 0.9 versus 1.5 ± 0.7, P = 0.001) and initial FiO₂ (0.51 ± 0.09 versus 0.44 ± 0.06, P < 0.001) when compared with patients successfully treated with HFNC. However, age, etiology for AHRF, and comorbidities were not significantly different between patient failing or not failing HFNC. The median duration of HFNC treatment in the success and failure groups was 78 (52–96) hours and 7 (6–23) hours, respectively. Among HFNC failure group, 18 patients (62.1%) were initiated on MV within 12 hours. Patients failing HFNC had higher ICU mortality (34.5% versus 0, P < 0.001), hospital mortality

Figure 1. Respiratory variables during HFNC treatment: At time 0 hours, no significant difference was found in ROX index between HFNC failure and HFNC success, whereas VOX index (and VT) was already significantly different at 0 hours, and remained the most powerful predictor for failure during the first 6 hours of HFNC treatment. FiO₂ = fraction of inspired oxygen; HFNC = high-flow nasal cannula; LPM = liters per minute; PBW = predicted body weight; ROX = respiratory rate-OXygenation; SpO₂ = pulse oximetry; VOX = Volume-OXygenation. *P < 0.05; **P < 0.01.
(37.9% versus 3.0%, \( P < 0.001 \)), and longer ICU length of stay (11 versus 6 days, \( P = 0.012 \)), compared HFNC success patients.

Between HFNC success and failure group, no significant differences in the respiratory rate were found at 0, 2, and 6 hours (Figure 1B). Whereas, VT per predicted body weight (PBW) at 0 h (8.2 ± 1.3 vs. 10.6 ± 2.2 ml/kg; \( P < 0.001 \)), 2 h (8.1 ± 1.4 vs. 11.1 ± 2.5 ml/kg; \( P < 0.001 \)), and 6 h (7.9 ± 1.2 vs. 11.2 ± 2.8 ml/kg; \( P < 0.001 \)) were all significantly higher in the HFNC failure group (Figure 1C).

Although no difference was found in the ROX index at 0 h between success and failure patients, the HFNC success group had significantly higher VOX index compared with failure group at 0 h (27.91 ± 7.13 vs. 19.16 ± 5.58; \( P < 0.001 \)), 2 h (28.89 ± 7.10 vs. 18.21 ± 6.78; \( P < 0.001 \)), and 6 h (30.68 ± 7.38 vs. 17.46 ± 6.18; \( P < 0.001 \)) (Figures 1E and 1F).

After adjusting for age, gender, APACHE II, and oxygenation, VOX > 24.82 at 0 hours (odds ratio [OR] 0.81 [95% confidence interval (CI), 0.69–0.94]; \( P = 0.007 \)), VOX > 20.91 at 2h (OR 0.78 [95% CI, 0.67–0.91]; \( P = 0.002 \)) and VOX > 22.67 at 6 hours (OR 0.66 [95% CI, 0.51–0.86]; \( P = 0.002 \)) were associated with lower risk for HFNC failure. AUROC values of different variables at 0, 2, and 6 hours, which were used to predict the failure of HFNC treatment, are reported in Table 1. Among all the variables, the prediction success and failure patients, the HFNC success group had significantly higher VOX index compared with failure group at 0 h (27.91 ± 7.13 vs. 19.16 ± 5.58; \( P < 0.001 \)), 2 h (28.89 ± 7.10 vs. 18.21 ± 6.78; \( P < 0.001 \)), and 6 h (30.68 ± 7.38 vs. 17.46 ± 6.18; \( P < 0.001 \)) (Figures 1E and 1F).

Discussion

We present the VOX index (\( \text{SpO}_2/\text{FiO}_2 \) to VT), as a novel early predictor for HFNC failure in patients with AHRF. This index is based on the premise that VT is a better estimate early increase in respiratory drive compared with respiratory rate, a key component of the ROX index. After adjusting for potential confounding, higher VOX index remained independently linked to a lower risk for HFNC failure. VOX index had a discriminatory potential of 0.88 (0.79–0.97) and 0.93 (95% CI, 0.86–0.99) in estimating HFNC failure within the first 2 and 6 hours of HFNC onset.

Roca and colleagues introduced the ROX index to predict HFNC failure in patients with hypoxic pneumonia. Consistent with the original study (4, 5), in the current study, ROX index was associated with HFNC failure. However, the VOX index appears to have a better predictive performance. In fact, VOX could already reliably predict HFNC failure at initiation of HFNC (ROC 0.84). Moreover, the overall discriminatory ability of VOX index was superior to that of ROX index for identification of HFNC failure at all the time points studied. There are some possible explanations for the superior performance of VOX compared with ROX. Even though respiratory drive constitutes a frequency component, respiratory rate alone is a rather insensitive marker for the quantification of respiratory drive and effort. In fact, respiratory rate increased only when respiratory drive was 3 to 4 times higher than normal (8). In our study, patients requiring MV did not exhibit higher respiratory rate than patients successfully treated with HFNC. Our data may further underline the inability of respiratory rate alone to identify patients with harmful respiratory drive. Nonintubated patients with AHRF may exhibit a high respiratory drive resulting in intense inspiratory effort, thus generating the inflation of high VT (9). We observed that patients requiring MV were more likely to generate high VT (>10 ml/kg) at HFNC initiation compared with patients successfully treated with HFNC. Interestingly, Carteaux (10) reported high tidal volume is independently associated with NIV failure in patients with acute hypoxemic failure. Also, Tonelli (7) reported that higher tidal volume, but not respiratory rate, are independently associated with NIV failure in hypoxemic patients. These studies support the important role of TV in failure of noninvasive respiratory support in acute hypoxemic failure patients. This is a likely explanation for the better performance of VOX (incorporating VT), compared with ROX.

This study has limitations. First, measurement of VT required interruption of HFNC and a short period of NIV for diagnostic purposes. This is cumbersome, and more feasible methods for assessment of VT should be used in future validation studies. Second, we used low levels of support during NIV, to guarantee patient comfort and arbitrarily mimic level of support during HFNC. Finally, given the fact that this was a single center study, with a relatively small number of patients, VOX requires further validation. Nevertheless, our findings are important for

### Table 1. Diagnostic Accuracy of Different Respiratory Variables at Different Time Points of Need for IMV in Patients Treated With HFNC

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>AUROC</th>
<th>95% CI</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{SpO}_2/\text{FiO}_2 )</td>
<td>0</td>
<td>0.76</td>
<td>0.64–0.89</td>
</tr>
<tr>
<td>2</td>
<td>0.82</td>
<td>0.71–0.93</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>6</td>
<td>0.84</td>
<td>0.73–0.95</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ROX index</td>
<td>0</td>
<td>0.50**</td>
<td>0.35–0.64</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0.42**</td>
<td>0.28–0.56</td>
</tr>
<tr>
<td>6</td>
<td>0.51**</td>
<td>0.36–0.66</td>
<td>0.893</td>
</tr>
<tr>
<td>VT (ml/kg of PBW)</td>
<td>0</td>
<td>0.66**</td>
<td>0.52–0.80</td>
</tr>
<tr>
<td>2</td>
<td>0.70*</td>
<td>0.56–0.85</td>
<td>0.006</td>
</tr>
<tr>
<td>6</td>
<td>0.79**</td>
<td>0.68–0.91</td>
<td>0.001</td>
</tr>
<tr>
<td>VOX index</td>
<td>0</td>
<td>0.83</td>
<td>0.71–0.94</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0.87</td>
<td>0.77–0.97</td>
</tr>
<tr>
<td>6</td>
<td>0.87</td>
<td>0.76–0.98</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*\( P < 0.001 \) compared with VOX index at the same time point. **\( P < 0.01 \) compared with VOX index at the same time point.
the design of larger prospective multicenter clinical trials aimed at validating the VOX index and determining the optimal intubation time.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Dongyu Chen, M.D.
Zhongda Hospital, School of Medicine
Southeast University
Nanjing, China

Leo Heunks, M.D., Ph.D.
Erasmus University Medical Center
Rotterdam, the Netherlands

Chun Pan, M.D., Ph.D.
Jianfeng Xie, M.D., Ph.D.
Haibo Qiu, M.D., Ph.D.
Yi Yang, M.D., Ph.D.1
Ling Liu, M.D., Ph.D.1
Zhongda Hospital, School of Medicine
Southeast University
Nanjing, China

ORCID ID: 0000-0001-6431-6352 (L.L.).

1These authors contributed equally to this work.

References


Copyright © 2022 by the American Thoracic Society

Upper and Lower Airway Dysanapsis and Airflow Obstruction among Older Adults

To the Editor:

The human airway tree is the conduit for gas exchange and can be divided anatomically into upper and lower airways based on location relative to the vocal cords. The upper and lower airways are connected in series but have distinct embryologic programs, the former arising mainly from the pharyngeal arches and the latter arising from the ventral primitive foregut.

Dysanapsis refers to an anthropometric mismatch between airway caliber and lung size that was first inferred from interindividual variability of maximum inspiratory airflow among healthy adults and hypothesized to contribute to chronic obstructive pulmonary disease (COPD) susceptibility later in life (1). Using computed tomography (CT), dysanapsis of the lower airway has been demonstrated in the general population (2), extending from trachea to terminal bronchioles (3), and is associated with significant COPD risk among older adults (2). Whether dysanapsis extends to the upper airway is uncertain, as is the association of upper airway caliber with airflow obstruction.

We tested the hypotheses 1) that the correlation between upper and lower airway caliber, independent of lung volume and potential confounders, would be weak or absent based on their distinct embryologic origins; and 2) that smaller upper airway caliber would be associated with airflow obstruction independent of lower airway caliber on the basis of their serial connectivity.

Some of these results were presented in abstract form to the American Thoracic Society International Conference (4).

Methods

The MESA (Multi-Ethnic Study of Atherosclerosis) is a community-based cohort that recruited 6,814 non-Hispanic White, Black, Hispanic, and Chinese American participants aged

Supported by NHLBI grants R01-HL130506, R01-HL077612, R01-HL098433, and R01-HL127659 and contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, R01-HL155816, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences.

Author Contributions: Conception and design: B.M.S., E.A.H., S.R., R.J.S., R.G.B., and S.R.H. Analysis and interpretation: all authors. Drafting the manuscript for important intellectual content: all authors. Originally Published in Press as DOI: 10.1164/rcrn.202202-0353LE on June 9, 2022